Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raju, U.
Right arrow Articles by Milas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raju, U.
Right arrow Articles by Milas, L.
[Cancer Research 63, 3263-3267, June 15, 2003]
© 2003 American Association for Cancer Research


Experimental Therapeutics

Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Enhances Radiosensitivity of Ovarian Carcinoma Cells1

Uma Raju2, Eiko Nakata, Kathy A. Mason, K. Kian Ang and Luka Milas

Departments of Experimental Radiation Oncology [U. R., E. N., K. A. M., L. M.] and Radiation Oncology [K. K. A.], The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030

Flavopiridol, a cyclin-dependent kinase (cdk) inhibitor, can cause cell cycle arrest, induce apoptosis in cancer cells, and inhibit tumor cell growth in vivo. The present study investigated the in vitro radiosensitizing effect of flavopiridol and the underlying molecular mechanisms in a murine ovarian cancer cell line, OCA-I. Flavopiridol inhibited cell growth in a dose-dependent manner and enhanced cell radiosensitivity assessed by the clonogenic cell survival assay. A flavopiridol dose of 300 nM, given for 1 day, enhanced radiosensitivity by a factor of 2.1. Clonogenic cell survival after split-dose radiation showed that flavopiridol inhibited repair from radiation damage. In addition, flavopiridol treatment (300 nM, 1 day) resulted in decreased levels of Ku70 and Ku86 proteins that play a role in DNA repair processes, suggesting that DNA repair processes may have been disrupted by this agent. Flow cytometry analysis showed that flavopiridol (300 nM, 1 day) accumulated the cells in G1 and G2 phases, with a significant reduction in the S phase component. This cell cycle redistribution is likely another mechanism underlying flavopiridol-induced cell radiosensitivity. Flavopiridol down-regulated cyclin D1 and cyclin E protein levels and also inhibited phosphorylation of retinoblastoma protein, which is inconsistent with the observed cell cycle arrest. Among the cdks tested, cdk-9, the catalytic subunit of positive transcription elongation factor b, was significantly down-regulated by flavopiridol, suggesting that flavopiridol may modulate cellular transcription processes. Furthermore, flavopiridol on its own induced apoptosis in the OCA-I cells, whereas in combination with radiation, exerted no additional increase in apoptosis. Taken together, our data show that flavopiridol strongly augmented the response of ovarian carcinoma cells to radiation and that the underlying mechanisms included inhibition of sublethal DNA damage repair and cell cycle redistribution. At the molecular level, transcriptional regulation by flavopiridol may have been involved.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Kunigal, S. S. Lakka, P. Joseph, N. Estes, and J. S. Rao
Matrix metalloproteinase-9 Inhibition Down-Regulates Radiation-Induced Nuclear Factor-{kappa}B Activity Leading to Apoptosis in Breast Tumors
Clin. Cancer Res., June 1, 2008; 14(11): 3617 - 3626.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. von Holzen, A. Pataer, U. Raju, D. Bocangel, S. A. Vorburger, Y. Liu, X. Lu, J. A. Roth, B. B. Aggarwal, G. N. Barber, et al.
The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor {kappa}B and Akt Activation
Clin. Cancer Res., October 15, 2007; 13(20): 6032 - 6039.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Garcia-Barros, D. Lacorazza, H. Petrie, A. Haimovitz-Friedman, C. Cardon-Cardo, S. Nimer, Z. Fuks, and R. Kolesnick
Host Acid Sphingomyelinase Regulates Microvascular Function Not Tumor Immunity
Cancer Res., November 15, 2004; 64(22): 8285 - 8291.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res., May 15, 2004; 64(10): 3653 - 3660.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Camphausen, K. J. Brady, W. E. Burgan, M. A. Cerra, J. S. Russell, E. E.A. Bull, and P. J. Tofilon
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of {gamma}H2AX foci
Mol. Cancer Ther., April 1, 2004; 3(4): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
R. Kolesnick and Z. Fuks
Response to Comments on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis"
Science, December 12, 2003; 302(5652): 1894e - 1894e.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Jung, M. Motwani, J. Kortmansky, F. M. Sirotnak, Y. She, M. Gonen, A. Haimovitz-Friedman, and G. K. Schwartz
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates {gamma}-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells
Clin. Cancer Res., December 1, 2003; 9(16): 6052 - 6061.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.